Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival

Table 7 Univariate and multivariate analyses of clinical factors related to overall survival in malignant melanoma

Factor	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age, yr
< 75	1			1
≥ 75	1.717	1.067-2.761	0.026	1.474	0.816-2.663	0.199
Sex
Male	1			1
Female	0.593	0.354-0.993	0.047	0.793	0.418-1.506	0.479
BMI, kg/m2
Underweight (< 18.5)	1
Normal (18.5-24.9)	1.252	0.671-2.336	0.48
Overweight (> 25.0)	1.044	0.510-2.137	0.906
Stage
III	1
IV	1.758	0.838-3.686	0.135
ECOG PS
0-1	1			1
2-3	3.014	1.427-6.366	0.004	2.406	1.125-5.147	0.024
GI-irAE
Continued administration of ICIs	1			1
Discontinued administration of ICIs	3.818	0.767-18.996	0.102	4.079	0.779-21.368	0.096
Non-GI-irAEs	3.25	1.020-10.360	0.046	3.081	0.963-9.861	0.058
ICI
Anti PD-1/PD-L1 antibody	1
Anti CTLA-4 antibody	1.366	0.837-2.228	0.212

BMI: Body mass index; CI: Confidence interval; CTLA-4: Cytotoxic T-lymphocyte antigen 4; GI-irAE: Gastrointestinal-immune-related adverse event; HR: Hazard ratio; ICI: Immune checkpoint inhibitor; PD-1: Programmed cell death-1.